Adma Biologics (ADMA) Accumulated Expenses (2011 - 2025)

Adma Biologics has reported Accumulated Expenses for 13 years, with the latest figure at $172000.0 in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses fell 94.84% year-over-year to $172000.0; the trailing twelve-month figure through Dec 2025 stood at $172000.0 (down 94.84% YoY), and the FY2025 full-year result was $172000.0, down 94.84% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $172000.0, up from $105000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $28.7 million in Q2 2023, with the low at $105000.0 in Q3 2025.
• Historically, Accumulated Expenses has averaged $6.8 million across 5 years, with a median of $3.4 million in 2024.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 1372.8% — and 2025, when it sank 96.95%.
• Adma Biologics' Accumulated Expenses stood at $1.2 million in 2021, then jumped by 250.28% to $4.2 million in 2022, then slumped by 86.98% to $546000.0 in 2023, then surged by 510.26% to $3.3 million in 2024, then sank by 94.84% to $172000.0 in 2025.
• The last three Accumulated Expenses figures came in at $172000.0 (Q4 2025), $105000.0 (Q3 2025), and $3.4 million (Q2 2025), per Business Quant data.